Prudential’s results were in line with market expectations. The 13% NBP growth was driven by a strong turnaround in mainland China and Malaysia, which largely offset the slowdown in Indonesia and Singapore. Hong Kong NBP growth also moderated in 2H25, due to frontloaded sales ahead of a few regulatory changes. OPAT per share, OFSG, and DPS met management's double-digit growth guidance in 2025, and management expects a similar growth trajectory to be maintained in 2026. Maintain BUY. Target price...
Top Stories Company Results | Fuyao Glass (3606 HK/BUY/HK$60.25/Target: HK$105.00) FYG’s 4Q25 GAAP net profit missed expectations at Rmb2,248m (+11.3% yoy/-0.5% qoq), due to forex losses. Stripping out one-off items, adjusted net profit met estimates at Rmb2,427m (+36.2% yoy/+4.0% qoq) on a yoy margin expansion. Its earnings outlook remains brilliant, backed by: a) continuous market share gain overseas, b) ASP increase on product mix optimisation, and c) its aluminium trim business. Maintain 20...
Greater China Company Results | Fuyao Glass (3606 HK/BUY/HK$60.25/Target: HK$105.00) FYG’s 4Q25 GAAP net profit missed expectations at Rmb2,248m (+11.3% yoy/-0.5% qoq), due to forex losses. Stripping out one-off items, adjusted net profit met estimates at Rmb2,427m (+36.2% yoy/+4.0% qoq) on a yoy margin expansion. Its earnings outlook remains brilliant, backed by: a) continuous market share gain overseas, b) ASP increase from optimisation of product mix, and c) its aluminium trim business. M...
We expect Prudential to report >10% growth in NBP, earnings and free surplus generation in 2025, in line with management guidance. It also announced that it would utilise part of the US$1.4b net proceeds from the IPAMC IPO to conduct a US$700m share buyback, with the remainder to be distributed in 2027. With a solid 5% yield and attractive growth outlook over the next two years, we believe Prudential continues to offer attractive upside potential. Maintain BUY. Target price: HK$138.00.
Top Stories Company Update | Prudential (2378 HK/BUY/HK$123.40/Target: HK$138.00) We expect Prudential to report >10% growth in NBP, earnings and free surplus generation in 2025, in line with management guidance. It also announced that it would utilise part of the US$1.4b net proceeds from the IPAMC IPO to conduct a US$700m share buyback, with the remainder to be distributed in 2027. With a solid 5% yield and attractive growth outlook over the next two years, we believe Prudential continues to ...
Greater China Company Update | Prudential (2378 HK/BUY/HK$123.40/Target: HK$138.00) We expect Prudential to report >10% growth in NBP, earnings and free surplus generation in 2025, in line with management guidance. It also announced that it would utilise part of the US$1.4b net proceeds from the IPAMC IPO to conduct a US$700m share buyback, with the remainder to be distributed in 2027. With a solid 5% yield and attractive growth outlook over the next two years, we believe Prudential continues to...
A director at Prudential sold 99,500 shares at 1,066p and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Prudential’s NBP grew 14% yoy in 3Q25, slightly above our forecast of 13% yoy, driven by an accelerated sales growth of 12% yoy and modest margin improvement. China, Hong Kong and other growth markets reported double-digit NBP growth. With the solid 3Q25 performance, Prudential is well on track to meet its 2025 NBP guidance. However, we expect a muted share price reaction, given limited disclosure on other financial metrics. Maintain BUY with an unchanged target price of HK$128.00.
Greater China Company Results | ASMPT (522 HK/BUY/HK$83.85/Target: HK$104.00) ASMPT’s 3Q25 print missed expectations on a weaker product mix and one-off restructuring costs. Revenue was largely in line with the mid-point of its guidance, but gross margin was below expectations at 35.7% due to changes in product mix and inventory write-off from the restructuring. Nevertheless, ASMPT reported solid progress with TCB in both HBM4 and advanced logic C2W/C2S, while its mainstream tools continued to r...
Top Stories Company Results | ASMPT (522 HK/BUY/HK$83.85/Target: HK$104.00) ASMPT’s 3Q25 print missed expectations on a weaker product mix and one-off restructuring costs. Revenue was largely in line with the mid-point of its guidance, but gross margin was below expectations at 35.7% due to changes in product mix and inventory write-off from the restructuring. Nevertheless, ASMPT reported solid progress with TCB in both HBM4 and advanced logic C2W/C2S, while its mainstream tools continued to re...
Prudential’s 1H25 results were broadly within our expectations with NBP growing at 12% yoy, mainly driven by Hong Kong, Indonesia and China. OPAT per share and gross OSFG were ahead of our estimates. On its capital management update, Prudential announced its DPS to grow over 10% in 2025-27, additional US$1.1b buybacks in 2026-27 and return of excess capital above 200% of free surplus ratio, implying over 5% yield in 2025-27. Maintain BUY. Target price: HK$128.00.
KEY HIGHLIGHTS Results Anhui Conch Cement (914 HK/BUY/HK$24.46/Target: HK$28.90) Anhui Conch Cement reported 1H25 earnings of Rmb4,367.9m (+31.3% yoy), representing 42.5% of our full-year estimates, slightly above expectations. Gross margin for self-produced products rose to 28.9% (+5.8ppt yoy). Cement ASP edged up 1.5% yoy, while unit production cost fell 7.1% yoy, mainly on a 13.8% drop in fuel and power costs. Cement and clinker sales volume was broadly stable at 126mt (-0.4% yoy), outperfo...
We expect Prudential to deliver 12% yoy NBP growth in 1H25, in line with management guidance, mainly driven by solid sales growth and continued margin expansion. The key point in its 1H25 results will be the capital management policy, and we expect Prudential to provide more clarity on its regular payout and planned use of net proceeds from the partial sale of its stake in IPAMC, which is likely to offer additional shareholder returns. Maintain BUY. Target price: HK$128.00.
KEY HIGHLIGHTS Results ASMPT (522 HK/BUY/HK$63.20/Target: HK$92.40) ASMPT’s 2Q25 results were largely in line, with revenue at the mid-point of its guided range, while bookings were a solid beat thanks to a bulk order from smartphone clients. The sustained improvement in orders momentum likely signals the beginning of a new capex cycle, while ongoing advances in AI-related products will likely bolster investor confidence in the near term. Maintain BUY and raise target price to HK$92.40. Upda...
Results ASMPT (522 HK/BUY/HK$63.20/Target: HK$92.40): 2Q25: Results largely in line. Solid bookings beat as mainstream tools recover; AP tools progressing well in logic and at HBM clients. Update Prudential (2378 HK/BUY/HK$98.10/Target: HK$128.00): 1H25 results preview: Expecting solid NBP growth and focusing on capital management. INDONESIA Small/Mid Cap Highlights Medco Energi Internasional (MEDC IJ/NOT RATED/Rp1,260): Disciplined strategy and portfolio diversification. MALAYSIA Update CIMB ...
China regulators have introduced several measures, allowing insurers to further raise their equity investment allocations. We estimate that insurers could reallocate Rmb900b to equities, supported by these regulatory tailwinds. However, insurers are likely to remain cautious due to earnings volatility and solvency headwinds from a declining long-term yield. Maintain MARKET WEIGHT. Top picks: Prudential and PICC P&C.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.